These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29933129)

  • 1. Differential Sensitivity of Human Hepatocellular Carcinoma Xenografts to an IGF-II Neutralizing Antibody May Involve Activated STAT3.
    Greenall SA; Donoghue J; Johns TG; Adams TE
    Transl Oncol; 2018 Aug; 11(4):971-978. PubMed ID: 29933129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A human monoclonal antibody against insulin-like growth factor-II blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo.
    Dransfield DT; Cohen EH; Chang Q; Sparrow LG; Bentley JD; Dolezal O; Xiao X; Peat TS; Newman J; Pilling PA; Phan T; Priebe I; Brierley GV; Kastrapeli N; Kopacz K; Martik D; Wassaf D; Rank D; Conley G; Huang Y; Adams TE; Cosgrove L
    Mol Cancer Ther; 2010 Jun; 9(6):1809-19. PubMed ID: 20515953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
    Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
    Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation.
    Huynh H; Chow PK; Ooi LL; Soo KC
    Cell Growth Differ; 2002 Mar; 13(3):115-22. PubMed ID: 11959812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum from Chronic Hepatitis B Patients Promotes Growth and Proliferation via the IGF-II/IGF-IR/MEK/ERK Signaling Pathway in Hepatocellular Carcinoma Cells.
    Ji Y; Wang Z; Chen H; Zhang L; Zhuo F; Yang Q
    Cell Physiol Biochem; 2018; 47(1):39-53. PubMed ID: 29763915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma.
    Sue SR; Chari RS; Kong FM; Mills JJ; Fine RL; Jirtle RL; Meyers WC
    Ann Surg; 1995 Aug; 222(2):171-8. PubMed ID: 7639583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
    Ji QS; Mulvihill MJ; Rosenfeld-Franklin M; Cooke A; Feng L; Mak G; O'Connor M; Yao Y; Pirritt C; Buck E; Eyzaguirre A; Arnold LD; Gibson NW; Pachter JA
    Mol Cancer Ther; 2007 Aug; 6(8):2158-67. PubMed ID: 17671083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells.
    Shimizu M; Shirakami Y; Sakai H; Tatebe H; Nakagawa T; Hara Y; Weinstein IB; Moriwaki H
    Cancer Lett; 2008 Apr; 262(1):10-8. PubMed ID: 18164805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
    Saraswati S; Alhaider A; Abdelgadir AM; Tanwer P; Korashy HM
    Cell Commun Signal; 2019 Oct; 17(1):127. PubMed ID: 31619257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis.
    Nussbaum T; Samarin J; Ehemann V; Bissinger M; Ryschich E; Khamidjanov A; Yu X; Gretz N; Schirmacher P; Breuhahn K
    Hepatology; 2008 Jul; 48(1):146-56. PubMed ID: 18537183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble mannose 6-phosphate/insulin-like growth factor II (IGF-II) receptor inhibits interleukin-6-type cytokine-dependent proliferation by neutralization of IGF-II.
    Duplomb L; Chaigne-Delalande B; Vusio P; Raher S; Jacques Y; Godard A; Blanchard F
    Endocrinology; 2003 Dec; 144(12):5381-9. PubMed ID: 12959977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of insulin, insulin-like growth factor-I and -II on proliferation and intracellular signaling in endometrial carcinoma cells with different expression levels of insulin receptor isoform A.
    Wang CF; Zhang G; Zhao LJ; Li XP; Qi WJ; Wang JL; Wei LH
    Chin Med J (Engl); 2013; 126(8):1560-6. PubMed ID: 23595395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of constitutively activated and insulin-like growth factor-stimulated ERK1/2 signaling in human hepatoma cell proliferation and apoptosis: evidence for heterogeneity of tumor cell lines.
    Alexia C; Lasfer M; Groyer A
    Ann N Y Acad Sci; 2004 Dec; 1030():219-29. PubMed ID: 15659801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of hepatocellular carcinoma growth by antisense oligonucleotides to type I insulin-like growth factor receptor in vitro and in an orthotopic model.
    Lin RX; Wang ZY; Zhang N; Tuo CW; Liang QD; Sun YN; Wang SQ
    Hepatol Res; 2007 May; 37(5):366-75. PubMed ID: 17441810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis.
    Alexia C; Fallot G; Lasfer M; Schweizer-Groyer G; Groyer A
    Biochem Pharmacol; 2004 Sep; 68(6):1003-15. PubMed ID: 15313394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of insulin-like growth factor II signaling by mutant type p53: physiological implications for potentiation of IGF-II signaling by p53 mutant 249.
    Lee YI; Han YJ; Lee SY; Lee YI; Park SK; Park YJ; Moon HB; Shin JH; Lee JH
    Mol Cell Endocrinol; 2003 May; 203(1-2):51-63. PubMed ID: 12782403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation Promotes Expression of Stemness-Related Properties in HBV-Related Hepatocellular Carcinoma.
    Chang TS; Chen CL; Wu YC; Liu JJ; Kuo YC; Lee KF; Lin SY; Lin SE; Tung SY; Kuo LM; Tsai YH; Huang YH
    PLoS One; 2016; 11(2):e0149897. PubMed ID: 26919045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.